Company Overview and News

 
Why Gold Is Performing Better than Silver

2018-04-09 marketrealist
When considering the performance of precious metals and precious metal mining companies, it’s important to analyze their interrelationship by way of ratios. There has been a significant up-and-down movement in the precious metals since the beginning of 2018. On a YTD (year-to-date) basis, gold has risen 1.4% and silver has fallen 4.3%. Silver has been weak compared to gold over the past few months.

1
Gold Mining Bull: Top News And Month In Review

2018-04-04 seekingalpha
Here's a monthly recap of the top news in the gold mining sector, including drill results, takeover announcements and other relevant updates, to keep readers up-to-date on news in the sector. Here's my update for February if you missed it.

 
Alamos Gold Provides Notice of First Quarter 2018 Results and Conference Call, Annual Meeting of Shareholders and Completion of Annual Filings

2018-03-29 globenewswire
TORONTO, March 29, 2018 (GLOBE NEWSWIRE) -- Alamos Gold Inc. (TSX:AGI) (NYSE:AGI) (“Alamos” or the “Company”) plans to release its first quarter 2018 financial results after market close on Tuesday, May 1, 2018. Senior management will host a conference call on Wednesday, May 2, 2018 at 11:00 am ET to discuss the results. The Company will hold its 2018 Annual Meeting of Shareholders (the “Annual Meeting”) on Monday, May 7, 2018.

 
5 Gold Stocks With Recent Insider Buying

2018-03-27 seekingalpha
I see insider buying as mostly a positive sign; it implies that insiders are bullish on company stock and think the price will rise.

 
Is the Correlation of Miners to Gold Strengthening or Weakening?

2018-03-22 editors.aws.marketrealist
Mining shares tend to move with gold prices. For our correlation analysis, we’ll compare gold with four mining stocks: Alamos Gold (AGI), First Majestic Silver (AG), B2Gold (BTG), and Royal Gold (RGLD). Mining funds also have high correlations with gold.

 
Manitou Gold Signs Binding Agreement to Acquire Goudreau-Lochalsh “Rockstar” Property

2018-03-21 globenewswire
SUDBURY, Ontario, March 21, 2018 (GLOBE NEWSWIRE) -- Manitou Gold Inc. (TSX-V:MTU) (the “Company” or “Manitou”) announces that it has entered into a binding purchase agreement with Argo Gold Inc. (the “Vendor”) to purchase the property known as the “Rockstar” Property, comprised of 16 unpatented mining claims located in Jacobson and Riggs Townships, Ontario (collectively, the “Property”).

 
Precious Metals Surged on Tuesday, March 13: Why?

2018-03-14 editors.aws.marketrealist
Early in the day on Tuesday, March 13, 2018, precious metals were having a down day as they waited for Consumer Price Index data. Precious metals also often slump before the Fed meets and decides whether or not to raise the interest rate. Precious metals are dollar-denominated assets that suffer from a rise in yield. The likely rate hike in the Fed’s meeting on March 20–21, 2018, seems to have already been priced in.

 
How Miners Correlate with Gold

2018-03-08 editors.aws.marketrealist
Precious metal mining stocks tend to take their cues from gold prices. Gold is the most crucial of the four precious metals, and the other three metals follow gold most of the time. For our correlation analysis, we’ll look at Alamos Gold (AGI), First Majestic Silver (AG), New Gold (NGD), and Newmont Mining (NEM). Mining-based funds have a high correlation with precious metals. The VanEck Vectors Junior Gold Miners ETF (GDXJ) and the Sprott Gold Miners (SGDM) rose 1.

 
How Movements in Precious Metals Impact Miners

2018-02-27 editors.aws.marketrealist
In this first part of our series, we’ll focus on four miners’ moving averages and RSI (relative strength index) readings. The miners we’ll analyze include Alamos Gold (AGI), First Majestic Silver (AG), New Gold (NGD), and Newmont Mining (NEM).

1
Alamos Gold's (AGI) CEO John McCluskey on Q4 2017 Results - Earnings Call Transcript

2018-02-23 seekingalpha
Good morning. I would now like to turn the meeting over to Mr. Jamie Porter, Chief Financial Officer. Please go ahead.

1
Osisko Gold Royalties Reports Fourth Quarter and Full Year 2017 Results

2018-02-20 marketwired
MONTREAL, QUEBEC--(Marketwired - Feb. 20, 2018) - Osisko Gold Royalties Ltd (the "Company" or "Osisko") (TSX:OR)(NYSE:OR) is pleased to report its results for the fourth quarter and full year 2017 and provide 2018 guidance. Amounts are in Canadian dollars unless otherwise noted.

 
Early Warning News Release

2018-02-17 marketwired
MONTRÉAL, QUÉBEC--(Marketwired - Feb. 16, 2018) - Osisko Gold Royalties Ltd (TSX:OR)(NYSE:OR) ("Osisko") announces that, pursuant to the terms of a share purchase agreement entered into with Alamos Gold Inc. on February 16, 2018, Osisko has acquired direct ownership of 25,300,000 common shares of Corex Gold Corporation ("Corex Gold") at a price of $0.13 per common share (the "Transaction").

2
What Miners’ Correlation Readings Indicate

2018-02-14 editors.aws.marketrealist
Mining stocks tend to move with gold prices. For our correlation analysis, we’ll compare four mining stocks to gold. We’ll look at Alamos Gold (AGI), First Majestic Silver (AG), B2Gold (BTG), and Royal Gold (RGLD).

 
GT Gold - Dr. Charles Tarnocai Joins Board; Option Grant

2018-01-29 marketwired
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan. 29, 2018) - GT Gold Corp. ("GT Gold" or the "Company") (TSX VENTURE:GTT) is pleased to announce that Dr. Charles Tarnocai has joined the Company's board of directors. Dr. Tarnocai has 22 years of experience in international mining and mineral exploration and was most recently Vice President, Corporate Development for Alamos Gold Inc. During his 7 years with Alamos Gold, he was responsible for the identification, financial and technical evaluation, and acquisition of development and production-stage mining projects.

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...